- Recent FDA approval of Amgen's Imdelltra (tarlatamab)
- ADCs from AbbVie (ABBV-706) targeting SEZ6
- ADCs from GSK/Hansoh (HS-20093) targeting B7-H3
- HPN328 (DLL3 TCE) from Harpoon Therapeutic update
- Results of Ph3 ADRIATIC study with Imfinzi in LS-SCLC
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Ticker(s): AMGN, ABBV, GSK, MRKWho's the expert?
Institution: Hummingbird Biotherapeutics
- Chief Medical Officer (part-time) of Hummingbird Biotherapeutics (formerly CMO at ImClone and Stemline Therapeutics).
- Focused on the comprehensive development and registration strategies of cancer therapeutics of all types; integrally involved with the development and registration of more than 12 cancer therapeutics.
- While at Johns Hopkins University School of Medicine, he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents; has published approximately 315 manuscripts in both the nonclinical and clinical research fields.
Interview GoalThis interview will focus on the SCLC space presented at ASCO 2024 including the following:
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
